N/A N=12,386 Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
N/A N=140 Medication Adherence in Individuals With Epilepsy
Epilepsy
Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days
Phase 2 N=39 Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
Epilepsy
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks) — 37 participants
Phase 2 N=49 Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
Epilepsy
Primary: Change in the Number of Seizure Days With Absence Seizures From the Baseline Phase to the Maintenance Phase — -0.37 number of seizure days
Phase 3 N=251 A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)
Epilepsy · Generalized Tonic-Clonic Seizures
Primary: Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation…
Phase 4 N=103 Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
Epilepsy, Idiopathic Generalized
Primary: Time to First Seizure — 169; 178 Days
Phase 3 N=239 Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
Epilepsy
Primary: Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period — 222 Participants
Phase 2 N=11 Pilot Study of Melatonin and Epilepsy
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Phase 2 N=126 Levetiracetam to Prevent Post-Traumatic Epilepsy
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Phase 4 N=54 Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
Partial Onset Seizures · Secondarily Generalized Seizures · Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment — 85.2 percentage of participants
Phase 3 N=163 A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
Seizure Disorder Generalized Tonic Clonic
Primary: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to…
Phase 3 N=180 Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
Partial-Onset or Primary Generalized Tonic-Clonic Seizures
Primary: Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) for Total Group of Participants - Core Phase…
Phase 3 N=605 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…
Phase 3 N=219 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
Generalized Tonic Clonic Seizures
Primary: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase — 1.17; 1.13; 1.14 Seizure…